Ophthalmology 360
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Photo Contest
    • Industry Council
    • Advisory Board

What are you looking for?

  • Anterior Segment
  • Cataract
  • Cornea and External Disease
  • Diabetic Macular Edema
  • Dry Eye
  • Early Onset Cataracts
  • Exclusives
  • General
  • Geographic Atrophy
  • Glaucoma
  • Industry News
  • Inherited Retinal Disease
  • IOLs
  • Neurotrophic Keratitis
  • Ocular Surface Disease
  • Oculoplastics
  • Optometry
  • Pediatrics
  • Practice Management
  • Presbyopia
  • Refractive Surgery/Vision Correction
  • Residents & Young Ophthalmologists
  • Retina
  • Retina Care 360
  • Retinopathy of Prematurity
  • Spotlight Series
  • The Interventional Glaucoma Project
  • The Ophthalmic Project
  • Trending Topics
2nd Annual Photo Contest - Enter Here!
Ophthalmology 360
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Photo Contest
    • Industry Council
    • Advisory Board
Home > Oculoplastics > Study first to examine TED manifestations in Black, Hispanic populations
  • Oculoplastics

Study first to examine TED manifestations in Black, Hispanic populations

Ophthalmology 360

In the first study to examine manifestations and severity of thyroid eye disease (TED) in a primarily Black and Hispanic patient population, researchers found overall higher rates of proptosis, extraocular muscle restriction, and optic neuropathy than in Caucasian populations, according to a presentation at ASOPRS 52nd Annual Fall Scientific Symposium.

In this retrospective cross-sectional study, the electronic medical records of 99 patients with TED (49.4% Black, 39.1% Hispanic, 9.2% Caucasian, 2.3% Asian) were reviewed. Most patients (78%) were women, and the mean age was 51 years.

Thyroid status included hyperthyroidism in 90.4%, hypothyroidism in 7.5%, and euthyroidism in 2.1%. A quarter of patients were current smokers and 14% were former smokers; these rates are higher than the US average. Manifestations included proptosis in 91%, eyelid retraction in 81%, extraocular muscle restriction in 69%, eyelid edema in 34%, chemosis in 17%, and optic neuropathy in 13%.

Most patients had moderate to severe disease (65%) followed by mild disease in 22% and sight-threatening disease in 13%. Statin use was associated with increased severity.

The researchers found that older patients had increased rates of optic neuropathy and younger patients had increased rates of proptosis.

“Understanding these differences can aid in making more swift and accurate diagnoses, thereby improving patient outcomes,” the study authors concluded.

Reference
Tingley J, Goldstein T, Mostowy M, et al. Thyroid Eye Disease (TED) Manifestations in a Primarily Black and Hispanic Population. Presented at: ASOPRS 52nd Annual Fall Scientific Symposium.

Share

Related Content

  • Oculoplastics

Pain measures may help track treatment response in Graves’ orbitopathy

FDA approves Eysuvis for short-term treatment of dry eye disease
  • Oculoplastics

FDA approves Lumvoa for active and chronic thyroid eye disease

Cornea Update: Corneal Dystrophies & Related Conditions with an Update on Genetic Assessment and Treatment
  • Cornea and External Disease

Preventing complications of superficial keratectomy

  • Oculoplastics

Blepharoplasty candidates prioritize function over aesthetics, survey finds

  • Oculoplastics

Integrating amniotic allografts into modern oculoplastic reconstruction: a practical perspective

  • The Ophthalmic Project

The next generation of amniotic membranes for the treatment of corneal epithelial defects

Share

Editor's Picks

  • Neurotrophic Keratitis

Topical insulin shows real-world benefit in neurotrophic keratopathy

  • Retina

GLP-1 RAs have protective effects against AMD

  • Retina

Four-month injection intervals appear safe for long-term stable nAMD

Advisory Board

Saad Ahmad, MD

Ahmad A. Aref, MD, MBA

Roomasa Channa, MD

David Chow, MD, FRCS(C)

Sally L. Baxter, MD, MSc

Neel R. Desai, MD

Nadia Haqqie, MD

Simon Fung, MD, FRCOphth

Sumit Garg, MD

Ross Lakhanpal, MD, FACS

Sanjai Jalaj, MD

Anton Kolomeyer, MD, PhD

Shan Lin, MD

Steven R. Sarkisian, Jr., MD

See All
Ophthalmology 360

Ophthalmology 360® is a dynamic digital platform dedicated to advancing the field of eye care.

Get to Know Us

  • Home
  • About Us
  • Media Partners
  • Advertising Policy
  • Our Advisory Board

Sign up for our Newsletter

Sign up for our Newsletter to get our newest articles instantly!

  • Privacy Policy
  • Advertising Policy
  • Medical Disclaimer
IHM Logo

2026 Ophthalmology 360 is a trademark of International Healthcare Media, LLC. All rights reserved

  • MedJournal360 Icon
  • RareDisease360 Icon
  • MyHero360 Icon
  • Optometry360 Icon
  • Ophtalmology360 Icon